-
1
-
-
84899438176
-
Colorectal cancer statistics, 2014
-
Siegel R, Desantis C, Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104-117, 2014
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 104-117
-
-
Siegel, R.1
Desantis, C.2
Jemal, A.3
-
2
-
-
79251470391
-
Projections of the cost of cancer care in the United States: 2010-2020
-
Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 117-128
-
-
Mariotto, A.B.1
Yabroff, K.R.2
Shao, Y.3
-
3
-
-
79954499886
-
Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
-
Wilhelm SM, Dumas J, Adnane L, et al: Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255, 2011
-
(2011)
Int J Cancer
, vol.129
, pp. 245-255
-
-
Wilhelm, S.M.1
Dumas, J.2
Adnane, L.3
-
4
-
-
84872921660
-
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial
-
Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
-
(2013)
Lancet
, vol.381
, pp. 303-312
-
-
Grothey, A.1
Van Cutsem, E.2
Sobrero, A.3
-
5
-
-
33745972934
-
∗28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
-
∗28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061-3068, 2006
-
(2006)
J Clin Oncol
, vol.24
, pp. 3061-3068
-
-
Toffoli, G.1
Cecchin, E.2
Corona, G.3
-
6
-
-
80053610056
-
Improved curve fits to summary survival data: Application to economic evaluation of health technologies
-
Hoyle MW, Henley W: Improved curve fits to summary survival data: Application to economic evaluation of health technologies. BMC Med Res Methodol 11:139, 2011
-
(2011)
BMC Med Res Methodol
, vol.11
, pp. 139
-
-
Hoyle, M.W.1
Henley, W.2
-
7
-
-
84862664604
-
-
New York, NY, Springer
-
Auget J-L, Balakrishnan N, Mesbah M, et al Advances in Statistical Methods for the Health Sciences. New York, NY, Springer, 2007
-
(2007)
Advances in Statistical Methods for the Health Sciences.
-
-
Auget, J.-L.1
Balakrishnan, N.2
Mesbah, M.3
-
8
-
-
0034922729
-
EQ-5D: A measure of health status from the EuroQol group
-
Rabin R, de Charro F: EQ-5D: A measure of health status from the EuroQol group. Ann Med 33:337-343, 2001
-
(2001)
Ann Med
, vol.33
, pp. 337-343
-
-
Rabin, R.1
De Charro, F.2
-
9
-
-
33748558111
-
Health state utilities for metastatic breast cancer
-
Lloyd A, Nafees B, Narewska J, et al: Health state utilities for metastatic breast cancer. Br J Cancer 95:683-690, 2006
-
(2006)
Br J Cancer
, vol.95
, pp. 683-690
-
-
Lloyd, A.1
Nafees, B.2
Narewska, J.3
-
11
-
-
84901937880
-
Optimizing treatment outcomes with regorafenib Personalized dosing and other strategies to support patient care
-
Grothey A, George S, van Cutsem E, et al Optimizing treatment outcomes with regorafenib Personalized dosing and other strategies to support patient care. Oncologist 19:669-680, 2014
-
(2014)
Oncologist
, vol.19
, pp. 669-680
-
-
Grothey, A.1
George, S.2
Van Cutsem, E.3
-
13
-
-
17544362070
-
Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis
-
Tumeh JW, Moore SG, Shapiro R, et al: Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 5:153-162, 2005
-
(2005)
Expert Rev Pharmacoecon Outcomes Res
, vol.5
, pp. 153-162
-
-
Tumeh, J.W.1
Moore, S.G.2
Shapiro, R.3
-
14
-
-
80052761895
-
A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer
-
Goulart B, Ramsey S: A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health 14:836-845, 2011
-
(2011)
Value Health
, vol.14
, pp. 836-845
-
-
Goulart, B.1
Ramsey, S.2
-
15
-
-
84927615521
-
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis
-
Goldstein DA, Chen Q, Ayer T, et al: First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis. J Clin Oncol 33:1112-1118, 2015
-
(2015)
J Clin Oncol
, vol.33
, pp. 1112-1118
-
-
Goldstein, D.A.1
Chen, Q.2
Ayer, T.3
-
16
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
-
Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Díaz-Rubio, E.3
-
17
-
-
49049105525
-
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study
-
Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 26:3523-3529, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 3523-3529
-
-
Hochster, H.S.1
Hart, L.L.2
Ramanathan, R.K.3
-
18
-
-
84871720057
-
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial
-
Bennouna J, Sastre J, Arnold D, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 14:29-37, 2013
-
(2013)
Lancet Oncol
, vol.14
, pp. 29-37
-
-
Bennouna, J.1
Sastre, J.2
Arnold, D.3
-
19
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
-
(2007)
J Clin Oncol
, vol.25
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
-
20
-
-
84902247358
-
Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC)
-
LBA388
-
Koopman M, Simkens L, May A, et al: Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 32, 2014 (suppl 3; abstr LBA388)
-
(2014)
J Clin Oncol
, vol.32
-
-
Koopman, M.1
Simkens, L.2
May, A.3
-
21
-
-
84867047384
-
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
-
Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 3499-3506
-
-
Van Cutsem, E.1
Tabernero, J.2
Lakomy, R.3
-
22
-
-
84930437602
-
RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp)
-
512
-
Tabernero J, Cohn AL, Obermannova R, et al: RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 33, 2015 (suppl 3; abstr 512)
-
(2015)
J Clin Oncol
, vol.33
-
-
Tabernero, J.1
Cohn, A.L.2
Obermannova, R.3
-
23
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 1408-1417
-
-
Van Cutsem, E.1
Köhne, C.H.2
Hitre, E.3
-
24
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E.1
Köhne, C.H.2
Láng, I.3
-
25
-
-
79956310674
-
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study
-
Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 22:1535-1546, 2011
-
(2011)
Ann Oncol
, vol.22
, pp. 1535-1546
-
-
Bokemeyer, C.1
Bondarenko, I.2
Hartmann, J.T.3
-
26
-
-
78049341541
-
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820, 2010
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Di Nicolantonio, F.3
-
27
-
-
84875742535
-
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab
-
Peeters M, Douillard JY, Van Cutsem E, et al: Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31:759-765, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 759-765
-
-
Peeters, M.1
Douillard, J.Y.2
Van Cutsem, E.3
-
28
-
-
78149250536
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
-
Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 4697-4705
-
-
Douillard, J.Y.1
Siena, S.2
Cassidy, J.3
-
29
-
-
84883680951
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
-
Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
-
(2013)
N Engl J Med
, vol.369
, pp. 1023-1034
-
-
Douillard, J.Y.1
Oliner, K.S.2
Siena, S.3
-
30
-
-
84905870196
-
PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer
-
Schwartzberg LS, Rivera F, Karthaus M, et al: PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240-2247, 2014
-
(2014)
J Clin Oncol
, vol.32
, pp. 2240-2247
-
-
Schwartzberg, L.S.1
Rivera, F.2
Karthaus, M.3
-
31
-
-
84879786289
-
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracilresistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial
-
Seymour MT, Brown SR, Middleton G, et al: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracilresistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial. Lancet Oncol 14:749-759, 2013
-
(2013)
Lancet Oncol
, vol.14
, pp. 749-759
-
-
Seymour, M.T.1
Brown, S.R.2
Middleton, G.3
-
32
-
-
84908573757
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial
-
Heinemann V, von Weikersthal LF, Decker T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 15:1065-1075, 2014
-
(2014)
Lancet Oncol
, vol.15
, pp. 1065-1075
-
-
Heinemann, V.1
Von Weikersthal, L.F.2
Decker, T.3
-
33
-
-
84871408435
-
In cancer care, cost matters
-
October 15
-
Bach PB, Saltz L, Wittes R: In cancer care, cost matters. New York Times, October 15, 2015:A25
-
(2015)
New York Times
, pp. A25
-
-
Bach, P.B.1
Saltz, L.2
Wittes, R.3
-
34
-
-
84927641527
-
Can money really be no object when cancer care is the subject?
-
Saltz LB: Can money really be no object when cancer care is the subject? J Clin Oncol 3:1093-1094, 2015
-
(2015)
J Clin Oncol
, vol.3
, pp. 1093-1094
-
-
Saltz, L.B.1
-
35
-
-
84938292355
-
The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: A critique of the evidence
-
Wade R, Duarte A, Simmonds M, et al: The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: A critique of the evidence. Pharmacoeconomics 33:457-466, 2015
-
(2015)
Pharmacoeconomics
, vol.33
, pp. 457-466
-
-
Wade, R.1
Duarte, A.2
Simmonds, M.3
-
36
-
-
33846477195
-
Costeffectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
-
Starling N, Tilden D, White J, et al: Costeffectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 96:206-212, 2007
-
(2007)
Br J Cancer
, vol.96
, pp. 206-212
-
-
Starling, N.1
Tilden, D.2
White, J.3
-
37
-
-
79551512524
-
Costeffectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer
-
Shiroiwa T, Motoo Y, Tsutani K: Costeffectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Ther 14:375-384, 2010
-
(2010)
Mol Diagn Ther
, vol.14
, pp. 375-384
-
-
Shiroiwa, T.1
Motoo, Y.2
Tsutani, K.3
-
38
-
-
69949157429
-
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial
-
Mittmann N, Au HJ, Tu D, et al: Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 101:1182-1192, 2009
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 1182-1192
-
-
Mittmann, N.1
Au, H.J.2
Tu, D.3
-
39
-
-
80053475784
-
KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective
-
Blank PR, Moch H, Szucs TD, et al: KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 17:6338-6346, 2011
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6338-6346
-
-
Blank, P.R.1
Moch, H.2
Szucs, T.D.3
-
40
-
-
84870878845
-
Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer
-
Behl AS, Goddard KA, Flottemesch TJ, et al: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. J Natl Cancer Inst 104:1785-1795, 2012
-
(2012)
J Natl Cancer Inst
, vol.104
, pp. 1785-1795
-
-
Behl, A.S.1
Goddard, K.A.2
Flottemesch, T.J.3
-
41
-
-
39049148881
-
Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan: A Belgian analysis
-
Annemans L, Van Cutsem E, Humblet Y, et al: Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan: A Belgian analysis. Acta Clin Belg 62:419-425, 2007
-
(2007)
Acta Clin Belg
, vol.62
, pp. 419-425
-
-
Annemans, L.1
Van Cutsem, E.2
Humblet, Y.3
-
42
-
-
33751178148
-
Cetuximab in the treatment of metastatic colorectal cancer: A model-based costeffectiveness analysis
-
Norum J: Cetuximab in the treatment of metastatic colorectal cancer: A model-based costeffectiveness analysis. J Chemother 18:532-537, 2006
-
(2006)
J Chemother
, vol.18
, pp. 532-537
-
-
Norum, J.1
-
43
-
-
84861631258
-
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
-
Vijayaraghavan A, Efrusy MB, Göke B, et al: Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer 131:438-445, 2012
-
(2012)
Int J Cancer
, vol.131
, pp. 438-445
-
-
Vijayaraghavan, A.1
Efrusy, M.B.2
Göke, B.3
-
44
-
-
84891634642
-
A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer
-
Lange A, Prenzler A, Frank M, et al: A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. Eur J Cancer 50:40-49, 2014
-
(2014)
Eur J Cancer
, vol.50
, pp. 40-49
-
-
Lange, A.1
Prenzler, A.2
Frank, M.3
-
45
-
-
84882958463
-
Economic studies in colorectal cancer: Challenges in measuring and comparing costs
-
Yabroff KR, Borowski L, Lipscomb J: Economic studies in colorectal cancer: Challenges in measuring and comparing costs. J Natl Cancer Inst Monogr 2013:62-78, 2013
-
(2013)
J Natl Cancer Inst Monogr
, vol.2013
, pp. 62-78
-
-
Yabroff, K.R.1
Borowski, L.2
Lipscomb, J.3
-
46
-
-
0036738342
-
Health economic evaluations: The special case of end-stage renal disease treatment
-
Winkelmayer WC, Weinstein MC, Mittleman MA, et al: Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 22:417-430, 2002
-
(2002)
Med Decis Making
, vol.22
, pp. 417-430
-
-
Winkelmayer, W.C.1
Weinstein, M.C.2
Mittleman, M.A.3
-
47
-
-
58849090571
-
An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard
-
Lee CP, Chertow GM, Zenios SA: An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard. Value Health 12:80-87, 2009
-
(2009)
Value Health
, vol.12
, pp. 80-87
-
-
Lee, C.P.1
Chertow, G.M.2
Zenios, S.A.3
-
48
-
-
84907360483
-
Updating cost-effectiveness: The curious resilience of the $50, 000-per-QALY threshold
-
Neumann PJ, Cohen JT, Weinstein MC: Updating cost-effectiveness: The curious resilience of the $50, 000-per-QALY threshold. N Engl J Med 371:796-797, 2014
-
(2014)
N Engl J Med
, vol.371
, pp. 796-797
-
-
Neumann, P.J.1
Cohen, J.T.2
Weinstein, M.C.3
-
49
-
-
0033914269
-
Willingness to pay for a quality-adjusted life year: In search of a standard
-
Hirth RA, Chernew ME, Miller E, et al: Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 20:332-342, 2000
-
(2000)
Med Decis Making
, vol.20
, pp. 332-342
-
-
Hirth, R.A.1
Chernew, M.E.2
Miller, E.3
-
50
-
-
84875467293
-
Consolidated Health Economic Evaluation Reporting Standards (CHEERS): Explanation and elaboration-A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
-
Husereau D, Drummond M, Petrou S, et al: Consolidated Health Economic Evaluation Reporting Standards (CHEERS): Explanation and elaboration-A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16:231-250, 2013
-
(2013)
Value Health
, vol.16
, pp. 231-250
-
-
Husereau, D.1
Drummond, M.2
Petrou, S.3
-
51
-
-
77958528027
-
What is the price benchmark to replace average wholesale price (AWP) ?
-
Curtiss FR, Lettrich P, Fairman KA: What is the price benchmark to replace average wholesale price (AWP) ? J Manag Care Pharm 16:492-501, 2010
-
(2010)
J Manag Care Pharm
, vol.16
, pp. 492-501
-
-
Curtiss, F.R.1
Lettrich, P.2
Fairman, K.A.3
-
52
-
-
59749092456
-
Limits on Medicare's ability to control rising spending on cancer drugs
-
Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
-
(2009)
N Engl J Med
, vol.360
, pp. 626-633
-
-
Bach, P.B.1
-
53
-
-
84924620555
-
Convergence of decision rules for value-based pricing of new innovative drugs
-
Gandjour A: Convergence of decision rules for value-based pricing of new innovative drugs. Expert Rev Pharmacoecon Outcomes Res 15:209-213, 2015
-
(2015)
Expert Rev Pharmacoecon Outcomes Res
, vol.15
, pp. 209-213
-
-
Gandjour, A.1
-
54
-
-
84922219447
-
Value-based differential pricing: Efficient prices for drugs in a global context
-
Danzon P, Towse A, Mestre-Ferrandiz J: Value-based differential pricing: Efficient prices for drugs in a global context. Health Econ 24:294-301, 2015
-
(2015)
Health Econ
, vol.24
, pp. 294-301
-
-
Danzon, P.1
Towse, A.2
Mestre-Ferrandiz, J.3
-
55
-
-
84880275207
-
Reforming the payment system for medical oncology
-
Bach PB: Reforming the payment system for medical oncology. JAMA 310:261-262, 2013
-
(2013)
JAMA
, vol.310
, pp. 261-262
-
-
Bach, P.B.1
-
56
-
-
84908150068
-
Indication-specific pricing for cancer drugs
-
Bach PB: Indication-specific pricing for cancer drugs. JAMA 312:1629-1630, 2014
-
(2014)
JAMA
, vol.312
, pp. 1629-1630
-
-
Bach, P.B.1
-
57
-
-
77949529722
-
Cancer's next frontier: Addressing high and increasing costs
-
Elkin EB, Bach PB: Cancer's next frontier: Addressing high and increasing costs. JAMA 303:1086-1087, 2010
-
(2010)
JAMA
, vol.303
, pp. 1086-1087
-
-
Elkin, E.B.1
Bach, P.B.2
-
58
-
-
35348976024
-
Satisfaction guaranteed: "Payment by results" for biologic agents
-
Garber AM, McClellan MB: Satisfaction guaranteed: "Payment by results" for biologic agents. N Engl J Med 357:1575-1577, 2007
-
(2007)
N Engl J Med
, vol.357
, pp. 1575-1577
-
-
Garber, A.M.1
McClellan, M.B.2
-
59
-
-
84919473012
-
Lowering medical costs through the sharing of savings by physicians and patients: Inclusive shared savings
-
Schmidt H, Emanuel EJ: Lowering medical costs through the sharing of savings by physicians and patients: Inclusive shared savings. JAMA Intern Med 174:2009-2013, 2014
-
(2014)
JAMA Intern Med
, vol.174
, pp. 2009-2013
-
-
Schmidt, H.1
Emanuel, E.J.2
|